曲普瑞林联合重组人生长激素治疗女童中枢性性早熟的临床疗效观察  

Therapeutic effect of triptorelin combined with recombinant human growth hormone on central precocious puberty in girls

作　　者：宋建[1] 崔北勇[1] 诸宏伟[2] SONG Jian;CUI Beiyong;ZHU Hongwei(Department of Pediatrics,Bengbu First People's Hospital,Bengbu,Anhui 233000,China;不详)

机构地区：[1]蚌埠市第一人民医院儿科,安徽蚌埠233000 [2]蚌埠医学院第一附属医院儿科,安徽蚌埠233004

出　　处：《中华全科医学》2023年第9期1544-1546,1551,共4页Chinese Journal of General Practice

基　　金：安徽省高校自然科学研究重点项目(KJ2021A0797)。

摘　　要：目的 研究曲普瑞林联合重组人生长激素治疗中枢性性早熟女童的临床效果。方法 选取2018年8月—2020年8月蚌埠市第一人民医院收治的中枢性性早熟女童60例,依据治疗方式不同,分为单独曲普瑞林治疗组(对照组)30例和曲普瑞林联合重组人生长激素治疗组(观察组)30例,观察2组女童治疗后性激素水平变化、胰岛素样生长因子1(IGF-1)和胰岛素样生长因子结合蛋白3(IGFBP-3)变化、临床疗效、不良反应发生率。结果 对照组与观察组治疗后的促卵泡生成素[(2.52±0.63)U/L vs.(2.42±0.56) U/L]、黄体生成素[(1.56±0.52)U/L vs.(1.62±0.60)U/L]、雌二醇[(10.84±2.50)ng/L vs.(12.10±3.20) ng/L]比较,差异无统计学意义(均P>0.05)。治疗后,与对照组比较,观察组IGF-1[(345.62±39.65)μg/L vs.(282.02±25.40)μg/L]、IGFBP-3[(5.54±2.64)mg/L vs.(4.22±1.46) mg/L]明显升高(均P<0.05)。治疗后,与对照组比较,观察组预测成年身高[(161.4±5.2) cm vs.(154.2±3.8) cm]、生长速度[(9.8±2.8) cm/年vs.(6.2±2.0) cm/年]显著增高(均P<0.05),但2组患儿骨龄比较差异无统计学意义[(10.3±0.5)岁vs.(10.1±0.7)岁,P>0.05]。2组患儿的不良反应轻微,发生率不高,通过治疗可以控制。结论 曲普瑞林联合重组人生长激素治疗女童中枢性性早熟疗效明显,对生长发育指标具有积极的意义,值得临床应用。Objective To study the clinical effect of triptorelin combined with recombinant human growth hormone in the treatment of girls with central precocious puberty(CPP).Methods Sixty girls with CPP admitted to Department of Pediatrics of Bengbu First People's Hospital from August 2018 to August 2020 were divided into control group(n=30)and study group(n=30).The control group was given triptorelin therapy,and the study group was given triptorelin combined with recombinant human growth hormone therapy.The changes of sex hormone level,insulin-like growth factor-1(ICF-1),insulin-like growth factor binding protein-3(IGFBP-3),clinical efficacy and incidence of adverse reactions were observed.Results There were no significant differences in the levels of FSH[(2.52+0.63)U/L vs.(2.42±0.56)U/L],LH[(1.56±0.52)U/L vs.(1.62±0.60)U/L]and E2[(10.84±2.50)ng/L us.(12.10±3.20)ng/LJ between the control group and the study group after treatment(P>0.05).IGF-1[(345.62±39.65)μg/L us.(282.02±25.40)μg/LJ and IGFBP-3[(5.54±2.64)mg/L us.(4.22±1.46)mg/L]levels in the study group were significantly higher than those in the control group after treatment,and the differences were statistically significant(all P<0.05).The levels of predicted adult height[(161.4±5.2)cm us.(154.2±3.8)cm]and growth velocity(9.8±2.8)cm per year us.(6.2±2.0)cm per year]in the study group were significantly higher than those in the control group,and the differences were statistically significant(all P<0.05).But there was no significant difference in bone age[(10.3±0.5)year of age us.(10.1±0.7)year of age]between the two groups after treatment(P>0.05).The adverse reactions of the two groups of children were mild,the incidence was not high and could be controlled by treatment.Conclusion Triptorelin combined with recombinant human growth hormone has a significant effect in the treatment of girls with CPP.It has positive significance for growth and development indicators,and is worthy of clinical promotion and application.

关 键 词：曲普瑞林 重组人生长激素 女童中枢性性早熟 临床疗效 

分 类 号：R729[医药卫生—儿科]